Elevation oncology investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of elevation oncology, inc. - elev

New york & new orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of elevation oncology, inc. (nasdaqcm: elev) to concentra biosciences, llc. under the terms of the proposed transaction, shareholders of elevation will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in e.
GM Ratings Summary
GM Quant Ranking